Product
VidPrevtyn® Beta
1 clinical trial
2 indications
Indication
Adverse Reaction to ImmunizationIndication
COVID-19Clinical trial
Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine: A Non-inferiority Multicenter Single-blinded, Randomized TrialStatus: Active (not recruiting), Estimated PCD: 2023-07-12